Deferred Revenue

Name: Alnylam Pharmaceuticals Deferred Revenue by Products & Services
Creator: OpenCapital
License: https://www.opencapital.sh/terms

Alnylam Pharmaceuticals·Products & Services·1 segment·Rolls up to Deferred Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Research Services Obligation	$41.47M	$45.47M	$41.16M	$27.3M	$15.08M	$2.54M	$4.8M	$3.2M
Total	$69.01M	$71.03M	$55.48M	$28.16M	$15.08M	$2.54M	$4.85M	$3.21M

Research Services ObligationView metric